Page 26 - Herpes Simplex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience February 11, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product candidate, Viralym-M (ALVR105), an allogeneic, off-the-shelf, multi-virus specific investigational T-cell therapy (VST), in allog...

Databridgemarketresearch.com Present “ Global Cold Sore Treatment Market– Industry Trends and Forecast to 2028” new report to its research database. Due to the potential of SWOT analysis and Porter’s Five Forces analysis in generating market research report, they are preferred by the businesses and hence also used while making this report. To structure such a world-class report, the combination of best industry insight, practical solutions, talent solutions and latest technology have been used. As today’s businesses demand the market research analysis to a great extent before taking...

Press release content from Accesswire. The AP news staff was not involved in its creation. AiCuris Changes its Legal Form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG February 1, 2021 GMT AiCuris shareholders elect Helga Rübsamen-Schaeff, Sean Marett and Helmut Jeggle to the inital Supervisory Board Supervisory board confirms Holger Zimmermann as CEO and Holger Schmoll as CFO WUPPERTAL, GERMANY / ACCESSWIRE / February 01, 2021 / AiCuris Anti-infective Cures GmbH (“AiCuris” or “the Company”), a leading company in the discovery and development of drugs against infectious disea...

Press release content from Business Wire. The AP news staff was not involved in its creation. EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China January 25, 2021 GMT HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 25, 2021-- EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for SYLVANT ® (siltuximab for injection) was accepted by the China National Medical Products Administration (NMPA) and granted p...

Press release content from Business Wire. The AP news staff was not involved in its creation. $450+ Million Herpes Marker Testing Market - Global Trajectory & Analytics to 2027 - ResearchAndMarkets.com January 19, 2021 GMT DUBLIN--(BUSINESS WIRE)--Jan 19, 2021-- Global Herpes Marker Testing Market to Reach $452.8 Million by 2027 Amid the COVID-19 crisis, the global market for Herpes Marker Testing estimated at US$328.6 Million in the year 2020, is projected to reach a revised size of US$452.8 Million by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027. ADVERTISEMENT Viral Cu...